China Life has returned for a $142m series D-plus round for cancer treatment developer Biocytogen, having already co-led its $77m series D round 13 months ago.

Biocytogen, the China-based developer of an antibody drug discovery platform, has closed a RMB970m ($142m) series D-plus round featuring China Life Investment, a vehicle for insurance provider China Life, DealStreetAsia reported today. The round was led by CMB International, a subsidiary of financial services firm China Merchants Bank, and included the state-owned SDIC Venture Capital,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.